| Biomarker ID | 580 |
| PMID | 21237555 |
| Year | 2011 |
| Biomarker | Methylation Status of [A4GALT; ADAM8; ALOX15B; BIK; CCK; CRCP; CTSC; CXCL2; CXCL3; CYBA; EIF4B; GSTM1 ; GSTM2; IGF2; LTF; MCAM; PDCD1; PDPN; PKMYT1; PPP1R3C; RAB32; RFTN1; SERPINB1; SLC16A5; SOCS1; TIMP3; TNF] |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | HyperMethylated in PCa ( Positive Fold change): [A4GALT(2.0 fold) ; ADAM8(3.9 fold); ALOX15B(5.1fold, 2.7 fold); BIK(2.6 fold); CCK(9.3 fold); CRCP(2.1fold); CTSC(3.7 fold); CXCL2(3.2 fold); CXCL3(3.0fold); CYBA(3.8 fold); EIF4B(3.5 fold); GSTM1 (20.5 fold); GSTM2(4.1 fold); IGF2(4.2 fold); LTF(2.1 fold); MCAM(2.7 fold); PDCD1(3.2 fold); PDPN(4.5 fold); PKMYT1(2.9 fold); PPP1R3C(8.2 fold) ; RAB32(3.3 fold); RFTN1(5.5 fold); SERPINB1(2.4 fold); SLC16A5(17.2fold, 4.2 fold); SOCS1(2.6 fold); TIMP3(2.2 fold); TNF(2.0 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Tumour Necrosis Factor alpha (TNF alpha) |
| Experiment | Tumor Vs Tumor Adjacent |
| Type of Biomarker | Diagnostic |
| Cohort | 17 patients with PCA tumors were analysed in the study. GEO Accession: GSE26319 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.013 |
| Method Used | real-time methylation-specific PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | A4GALT, ADAM8, ALOX15B, BIK, CCK, CRCP, CTSC, CXCL2, CXCL3, CYBA, EIF4B, GSTM1, GSTM2, IGF2, LTF, MCAM, PDCD1, PDPN, PKMYT1, PPP1R3C, RAB32, RFTN1, SERPINB1, SLC16A5, SOCS1, TIMP3, TNF |